Drugs / FP-101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05312567 | Mar 2021 → Apr 2023 | — | Fervent Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03285672 | Mar → Oct 2018 | — | Fervent Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03285672 ↗ |
| Route | Oral | “daily oral tablet administration (b.i.d.)” NCT05312567 ↗ |